Cardiology associations have released updated guidelines emphasizing personalized risk assessment. Modern biomarkers allow for more precise identification of at-risk individuals.
Lifestyle modification remains central, but new medications are available for patients with elevated lipoprotein levels. Shared decision-making with physicians is encouraged.
